Biotech Support Group Release: Patent Application Cites Cleanascite for Culturing Pancreatic Islets
MONMOUTH JUNCTION, NJ, January 11, 2018 -- Biotech Support Group reports on a recent patent application describing the simplicity and efficiency of their lipid clearance sample preparation technology for evaluating the influence of lipids on pancreatic islet culture.
The patent application is:
United States Patent Application 20170348398 entitled: " COMPOSITIONS AND METHODS FOR DECREASING BLOOD GLUCAGON LEVELS”
The patent discloses compositions and methods for decreasing blood glucagon levels. As disclosed, Lglutamine is a selective stimulator of α-cell proliferation generated when glucagon signaling is interrupted. A method for treating a subject with hyperglucagonemia, e.g., a subject with diabetes, that involves administering to the subject a composition comprising an L-glutamine inhibitor in an amount effective to decrease blood glucagon levels, is disclosed. In an example, pancreatic islets were isolated from male 8-14 week old C57B16/J mice (Jackson Laboratory, ME) and cultured in various media conditions for 3 days. The patent states “For lipid removal, serum was treated with Cleanascite reagent (Biotech Support Group, Monmouth Junction, N.J.) prior to islet culture at a 1:1 ratio according to the vendor's protocol.”. The example supports that increased amino acids, but not lipids and other soluble factors, selectively increased rapamycin-sensitive α-cell proliferation.
“This reference shows the versatility of Cleanascite™ to efficiently remove lipids from serum tissue culture, so that factors that influence cell proliferation can be investigated.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com
Matthew Kuruc 732-274-2866